Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?

Hemphill, Thomas A.

doi:10.1007/s10551-009-0259-x

Cited by 32 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods include illustrative examples and qualitative and quantitative studies. Most of the research has appeared in the Journal of Business Ethics (Hemphill, 2010;Bruyaka et al, 2013).…”

Section: Pharmaceuticalsmentioning

confidence: 99%

Industry-specific CSR: analysis of 20 years of research

Dabić

Colovic

Lamotte

et al. 2016

EBR

View full text Add to dashboard Cite

Access to this document was granted through an Emerald subscription provided by emeraldsrm:239791 [] For AuthorsIf you would like to write for this, or any other Emerald publication, then please use our Emerald for Authors service information about how to choose which publication to write for and submission guidelines are available for all. Please visit www.emeraldinsight.com/authors for more information. About Emerald www.emeraldinsight.comEmerald is a global publisher linking research and practice to the benefit of society. The company manages a portfolio of more than 290 journals and over 2,350 books and book series volumes, as well as providing an extensive range of online products and additional customer resources and services.Emerald is both COUNTER 4 and TRANSFER compliant. The organization is a partner of the Committee on Publication Ethics (COPE) and also works with Portico and the LOCKSS initiative for digital archive preservation. AbstractPurpose -The purpose of this study is to analyze the literature on industry-specific corporate social responsibility (CSR) practices. Design/methodology/approach -Using a multiple-keyword search, the authors identified 302 articles reporting on such practices, published in 99 different academic journals between 1995 and 2014. These articles were analyzed to map the CSR literature, identify which industries have been under greater scrutiny and distinguish trends in the most researched industries. Findings -The authors' findings indicate that the CSR studies are very unevenly distributed and that the issues studied and the methods used vary widely across industries. The authors also map this field of study and propose suggestions on where research on industry-specific CSR should go in the future. Originality/value -The first extensive, systematic analysis of the industry-specific CSR literature is provided. The current research adds value to the literature by highlighting the key issues investigated, as well as those that require further inquiry.

show abstract

“…Methods include illustrative examples and qualitative and quantitative studies. Most of the research has appeared in the Journal of Business Ethics (Hemphill, 2010;Bruyaka et al, 2013).…”

Section: Pharmaceuticalsmentioning

confidence: 99%

Industry-specific CSR: analysis of 20 years of research

Dabić

Colovic

Lamotte

et al. 2016

EBR

View full text Add to dashboard Cite

show abstract

“…22 This argument may be questioned since, in a market with legally sanctioned exclusivity, each company is the market; there are no other participants.…”

Section: How Might Companies Respond?mentioning

confidence: 99%

Orphan drug pricing may warrant a competition law investigation

Roos

Hyry

Cox

2010

BMJ

View full text Add to dashboard Cite

show abstract

“…There is a concern that pharmaceutical companies can create a monopoly market [6], precluding payers' ability to negotiate prices, by "splitting up a disease into several sub-diseases that qualify as rare diseases (a practice called 'disease sub-setting,' 'salami-slicing' or disease stratification')" [15]. Furthermore, drug manufacturers are "free to set their own introductory prices" [16], and "establishing a price that maximizes its profit is legal" [17]. Such high medication costs can be burdensome to payers and, especially but not only if reimbursement is denied, to patients.…”

Section: Successes Of the Odamentioning

confidence: 99%